Beta-blockade should not be among several choices for initial therapy of hypertension

Journal of Hypertension

Volumn 26, Issue 2, 2008, Pages 161-163

  Opie, Lionel H ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Angiotensin inhibitors; B blockers; Calcium blockers; Cardioprotection; Endothelial dysfunction; Erectile dysfunction

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOBESITY AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEBIVOLOL; NITRIC OXIDE; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; ARTERIAL PRESSURE; BRACHIAL ARTERY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DRUG ANTAGONISM; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HOSPITALIZATION COST; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 38149061361     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f300a7     Document Type: Review

References (29)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
2. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22:1453-1458.
3. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3-10.
4. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
5. Nilsson PM. Drug-induced new onset diabetes in hypertension: does it matter? J Hypertens 2007; 25:1201-1204.
6. Lam SK, Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet 2007; 369:1513-1514.
7. Gress TW, Nieto J, Shahar E, Wofford MR, Brancati FL. For the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensives therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342:905-912.
8. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
9. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116:151-157.
10. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50:467-473.
11. Mozaffarian D, Marfisi RM, Levantesi G, Silletta M, Tavazzi L, Tognani G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370:667.
12. Dählof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
13. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165:1410-1419.
14. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24:2131-2141.
15. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
16. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
17. Polonia J, Barbosa L, Bertochini S, Silva JA. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with beta-blockers either with or without associating properties [abstract]. Eur Heart J 2007; 28 (Suppl):767-768.
18. Bangalore S, Messerli FH, Kostis JB, Pepine C. Cardiovascular protection using beta blockers. J Am Coll Cardiol 2007; 50:563-572.
19. Study TAIM, Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am J Hypertens 1992; 5:37-44.
20. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study. Am J Hypertens 2001; 14:27-31.
21. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34:327-331.
22. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788.
23. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
24. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med 2005; 67:398-406.
25. UKPDS 39. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
26. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001; 37:250-254.
27. Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation 2007; 115:1973-1974.
28. Williams B. Beta-blockers and the treatment of hypertension. J Hypertens 2007; 25:1351-1353.
29. Seedat YK, Croasdale MA, Milne FJ, Opie LH, Pinkney-Atkinson VJ, Rayner BL, Veriava Y. South African hypertension guideline 2006. S Afr Med J 2006; 96:337-362.